<?xml version="1.0" encoding="UTF-8"?>
<ref id="B1">
 <label>1.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Schellekens</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Stegemann</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Weinstein</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>de Vlieger</surname>
    <given-names>JS</given-names>
   </name>
   <name>
    <surname>Flühmann</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Mühlebach</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider</article-title>. 
  <source>AAPS J</source>. (
  <year>2014</year>) 
  <volume>16</volume>:
  <fpage>15</fpage>–
  <lpage>21</lpage>. 
  <pub-id pub-id-type="doi">10.1208/s12248-013-9533-z</pub-id>
  <?supplied-pmid 24065600?>
  <pub-id pub-id-type="pmid">24065600</pub-id>
 </mixed-citation>
</ref>
